Yet another big Phase III test of an experimental Alzheimer's drug has flopped. And this time it's Roche's turn to admit defeat.
PPD has signed a data-minded deal with the collection experts at ERT, a partnership the companies believe will help their clients conduct more efficient trials.
China has approved a locally developed Ebola vaccine from its Academy of Military Medical Sciences for clinical trials, state news agency Xinhua said Thursday.
More than four years ago, GlaxoSmithKline began a Phase III study of a shingles candidate it hoped would eventually mount a challenge to Merck's Zostavax. Now, that candidate is one step closer after hitting its primary endpoint in that trial.
GlaxoSmithKline got some good news for its big vaccines group, scoring a pivotal Phase III win for its shingles vaccine HZ/su more than four years after the study was launched.
Shares of Tetraphase Pharmaceuticals spiked 15% Wednesday afternoon after the biotech said its lead antibiotic hit its primary endpoint in a head-to-head Phase III study, leaving the company on track to file for an approval before the end of next year.
Paris-based Neovacs got hammered yesterday after the biotech spread the word that its Phase IIb study of an experimental therapeutic vaccine for rheumatoid arthritis flopped.
Amgen's cancer vaccine candidate may be awaiting FDA and EMA approval as a melanoma monotherapy, but like many of its peers, it's also looking to explore its prospect's potential as part of an immunotherapy duo, and now it's kicked off a trial combining its treatment with Merck's anti-PD-1 therapy that should help it do just that.
Right now, there is no FDA-approved cholera vaccine for U.S. travelers heading to high-risk countries. A California company hopes to change that soon: On Monday, PaxVax said it planned to submit a Biologics License Application for its oral single-dose candidate in mid-2015.
Circassia Pharmaceuticals' pipeline has suffered its first notable post-IPO setback. The British biotech's ragweed allergy drug failed to live up to expectations in a Phase IIb trial, prompting the company to dig deeper into the data in search of a path forward for the candidate.